

2023 QCDR Measure ID	Measure Title	Measure Description	Denominator	Numerator	Denominator Exclusions	Denominator Exceptions	Numerator Exclusions	NQF ID	High Priority Measure	Measure Type	Includes Telehealth	Inverse Measure	Proportional Measure	Continuous Variable Measure	Ratio Measure	Number of performance rates to be calculated and submitted	Risk Adjusted	Submission Pathway	Care Setting
AQUA3	Hospital admissions or infectious complications within 30 days of prostate biopsy	Percentage of patients with urinary retention, infection, inpatient consultation, or hospital admission for infection or sepsis within 30 days of undergoing a prostate biopsy	Patients 18 years and older who underwent a prostate biopsy	Patients with urinary retention, infection or new antibiotic prescription at least 24 hours after, and within 30 days of prostate biopsy, or an inpatient consultation within 30 days of prostate biopsy, or infection or sepsis requiring hospitalization within 30 days of prostate biopsy	None	None	None	N/A	Yes	Outcome	No	Yes	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Hospital
AQUA14	Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment	Percentage of patients who underwent repeat Shock Wave Lithotripsy within 6 months of initial procedure	Patients 18 years and older who underwent an SWL procedure for the treatment of stones	Patients who underwent an ipsilateral SWL procedure within 6 months	None	None	None	N/A	Yes	Outcome	No	Yes	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital; Office Based Surgeon Center
AQUA15	Stones: Urinalysis Performed Before Surgical Stone Procedures	Percentage of patients with a documented urinalysis within 14 days prior to surgical stone procedures	Patients 18 years and older who underwent a surgical procedure for the treatment of stones	Patients with documented urinalysis within 14 days prior to surgery	None	None	None	N/A	Yes	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Outpatient Services
AQUA16	Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease	Percentage of patients with T1 disease who had a second transurethral resection of bladder tumor (TURBT) within 6 weeks of the initial TURBT	Patients 18 years and older diagnosed with clinical stage T1 bladder cancer	Patients with T1 disease who had a second TURBT within 6 weeks of the initial TURBT	None	Onset of systemic chemotherapy or radical cystectomy within 12 weeks of diagnosis	None	N/A	No	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital
AQUA18	Non-Muscle Invasive Bladder Cancer: Early Surveillance Cystoscopy for Non-Muscle Invasive Bladder Cancer	Percentage of patients who had surveillance cystoscopy 12 to 20 weeks after undergoing initial Transurethral Resection for Bladder Tumor (TURBT)	Patients 18 years and older diagnosed with bladder cancer who underwent initial TURBT	Patients who had surveillance cystoscopy 12 to 20 weeks after initial TURBT	None	Onset of systemic chemotherapy or radical cystectomy within 12 weeks of bladder cancer diagnosis	None	N/A	No	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic
AQUA26	Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPH	Percentage of patients with initial diagnosis of BPH who had a creatinine lab order placed or had a CT abdomen, MRI abdomen, ultrasound abdomen ordered or performed	Patients 18 years and older with an initial diagnosis of BPH	A. Patients who received an order for serum creatinine laboratory testing B. Patients who received an order for diagnostic imaging tests (CT Scan, MRI, abdominal ultrasound), or had the test performed C. Patients who received an order for serum creatinine laboratory testing or diagnostic imaging tests (CT Scan, MRI, abdominal ultrasound), or had the test performed	None	Patients with known renal insufficiency (Cr >1.5 or documented in past medical history) or with documented flank pain or hematuria within 30 days of initial BPH diagnosis; Patients with a urological surgical procedure within 30 days following order of SCl/maging; if the SCl/maging was ordered following initial BPH diagnosis; Patients with hyperensive kidney disease; Patients with urinary retention	None	N/A	Yes	Process	No	Yes	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Outpatient Services
MUSIC4	Prostate Cancer: Active Surveillance/Watchful Waiting for Newly Diagnosed Low Risk Prostate Cancer Patients	Proportion of patients newly diagnosed with low-risk prostate cancer managed with active surveillance or watchful waiting	Newly diagnosed low-risk prostate cancer patients age 30 or older	Patients on active surveillance or watchful waiting	Patients who have had prior treatment for prostate cancer	None	None	N/A	Yes	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Outpatient Services